Premium
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Author(s) -
Kim Kevin B.
Publication year - 2012
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.27756
Subject(s) - medicine , bevacizumab , vascular endothelial growth factor , melanoma , stromal cell , chemotherapy , oncology , neovascularization , clinical trial , angiogenesis , growth factor , cancer research , pharmacology , receptor , vegf receptors
Bevacizumab and other drugs targeting vascular endothelial growth factor and/or its receptor have shown encouraging clinical outcomes in early‐phase studies when they are combined with cytotoxic chemotherapy drugs. The success of bevacizumab or other antiangiogenic drugs in the treatment of patients with advanced melanoma will depend on a better understanding of tumoral neovascularization and its effect on tumor stromal tissues, as well as on selecting patients with appropriate relevant biomarkers to yield improved clinical outcomes.